Clinical implications of pharmacogenomics for tardive dyskinesia
- 25 March 2004
- journal article
- review article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 4 (2) , 77-87
- https://doi.org/10.1038/sj.tpj.6500233
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- CYP2D6 Polymorphism and Tardive Dyskinesia in Schizophrenic PatientsPharmacopsychiatry, 2003
- Brain imaging and pharmacogenetics in Alzheimer's disease and schizophreniaPublished by Cambridge University Press (CUP) ,2002
- Genetic factors underlying drug-induced tardive dyskinesiaPublished by Cambridge University Press (CUP) ,2002
- Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenicsThe Pharmacogenomics Journal, 2002
- Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophreniaMolecular Psychiatry, 2002
- Familial occurrence of tardive dyskinesiaActa Psychiatrica Scandinavica, 2001
- Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patientsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2001
- The Current Status of Tardive DyskinesiaAustralian & New Zealand Journal of Psychiatry, 2000
- Angiotensin‐Converting Enzyme Modulates Dopamine Turnover in the StriatumJournal of Neurochemistry, 1997
- Obstetric Complications, the Putative Familial-Sporadic Distinction, and Tardive Dyskinesia in SchizophreniaThe British Journal of Psychiatry, 1990